770703-20-3
Chemical Structure
L-97-1
- CAS No.: 770703-20-3
- Formula:C29H38N6O3
- Molecular Weight:518.65
IUPAC Name: 3-(4-aminophenethyl)-8-benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione
InChIKey: QVEHDKFBFDUCEZ-UHFFFAOYSA-N
SMILES: O=C(N1CCC)N(CCC2=CC=C(N)C=C2)C3=C(N(CCN(CC)CCO)C(CC4=CC=CC=C4)=N3)C1=O
Biological Activity: L-97-1 is a A1 adenosine receptor (A1AR) antagonist. L-97-1 is a water-soluble small molecule compound with high affinity and high selectivity against human A1 adenosine receptors. L-97-1 works by blocking A1 adenosine receptors. In patients with asthma, adenosine is an important signaling molecule capable of causing bronchoconstriction by activating A1AR. L-97-1 reduces airway hyperreactivity (BHR) by competitively binding to A1AR, thereby alleviating or blocking adenosine-induced bronchoconstriction and inflammation[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-97-1 | L-97-1 is a A1 adenosine receptor (A1AR) antagonist. L-97-1 is a water-soluble small molecule compound with high affinity and high selectivity against human A1 adenosine receptors. L-97-1 works by blocking A1 adenosine receptors. In patients with asthma, adenosine is an important signaling molecule capable of causing bronchoconstriction by activating A1AR. L-97-1 reduces airway hyperreactivity (BHR) by competitively binding to A1AR, thereby alleviating or blocking adenosine-induced bronchoconstriction and inflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Obiefuna P C M, et al. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2, 6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 315(1): 329-336. [Content Brief]
